Voluntary announcement - phase iii clinical trial of becotatug (jmt101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic nsclc harbouring egfr exon 20 insertion mutations achieves positive topline results
Filed with HKEX · Stock code 1093 ·
6ix hasn’t read this filing yet.
Earlier from Cspc Pharmaceutical
- Voluntary announcement - phase iii clinical trial of docetaxel for injection (albumin-bound) (hb1801) for the treatment of advanced breast cancer officially initiated in china
- Notification letter to shareholder and change request form
- Notification letter to non-registered holder and request form
- Letter to new registered shareholders and reply form